Vaccines help nations exit pandemic faster

The messenger RNA (mRNA) shots developed by Pfizer-BioNTech or Moderna are better at stopping people from becoming contagious, helping reduce onward transmission.

Other vaccines, while effective in preventing acute illness or death from Covid-19, appear not to have this extra perk to the same degree.

So get vaccinated, will ya?

We can't shut our borders for a long time or we will end up having our lives without a livelihood.

Singapore will make decisions on vaccines on the basis of science and healthcare needs

Singapore will make decisions on vaccines on the basis of science and healthcare needs. This is just another example of the way we conduct our policies.

We cannot be bought, we cannot be bullied, we cannot be intimidated into either approving or disapproving any vaccine.

We will make decisions on the basis of health and science.

There will be pressure for us, there will be push and pulls, but we must conduct this just like another example of foreign policy in a principled manner.

- Foreign Minister Vivian Balakrishnan

Do you know that vaccines will support our recovery in more ways than one, besides protecting our bodies from the virus?

Do you know that vaccines will support our recovery in more ways than one, besides protecting our bodies from the virus?

This is all the result of a very good government we enjoy and it is not an empty praise or blind adoration.

"As a global aviation hub, we play a crucial role transporting vaccines around the world.

Vaccines require cold chain management.

An ordinary refrigerator is not good enough: the Pfizer vaccine needs to be stored at minus 70 degrees Celsius, colder than the Arctic in winter!

This requires infrastructure, high standards, skilled personnel, and good connectivity to many different countries all along the supply chain.

Fortunately, Singapore has a strong ecosystem for cargo handling.

Leading global logistics companies like DHL, UPS and FedEx are based here. SIA, and Changi Airport’s ground handling partners are certified by IATA (International Air Transport Association) to handle and transport pharmaceutical supplies.

We are now gearing ourselves up to handle large volumes of vaccine shipments into and through Singapore, to help win the global fight against COVID-19.

We did not get here overnight. We have always planned ahead, systematically creating opportunities for ourselves. It took us years of investment and planning, building a business-friendly climate and expanding our air links around the world. These long-term investments are now paying dividends."

- PM Lee

Let this sink in.

COVID-19 vaccination: It's voluntary and it's free.

It's voluntary and it's free.

The Government has been working quietly to secure our supply before making this announcement.

Do get vaccinated and let's protect each other!

𝐎𝐮𝐫 𝐯𝐞𝐫𝐲 𝐨𝐰𝐧 𝐂𝐎𝐕𝐈𝐃-𝟏𝟗 𝐯𝐚𝐜𝐜𝐢𝐧𝐞 𝐠𝐨𝐞𝐬 𝐨𝐧 𝐡𝐮𝐦𝐚𝐧 𝐭𝐫𝐢𝐚𝐥𝐬...

𝐎𝐮𝐫 𝐯𝐞𝐫𝐲 𝐨𝐰𝐧 𝐂𝐎𝐕𝐈𝐃-𝟏𝟗 𝐯𝐚𝐜𝐜𝐢𝐧𝐞 𝐠𝐨𝐞𝐬 𝐨𝐧 𝐡𝐮𝐦𝐚𝐧 𝐭𝐫𝐢𝐚𝐥𝐬...

The COVID-19 vaccine candidate - LUNAR-COV19 - has been approved to proceed by the Singapore Health Sciences Authority. 👍👍

Arcturus and Duke-NUS partnered to develop it using Arcturus’ STARR™ technology and a unique platform developed at Duke-NUS allowing rapid screening of vaccines for potential effectiveness and safety.

Arcturus and Duke-NUS will initiate human dosing of LUNAR-COV19 as soon as possible.

The healthy volunteer study will evaluate several dose levels of LUNAR-COV19 in up to 108 adults, including older adults.

Follow-up will be conducted to evaluate safety, tolerability and the extent and duration of the humoral and cellular immune response.

Professor Ooi Eng Eong, Deputy Director of the Emerging Infectious Diseases Program at Duke-NUS, said, “Preclinical studies on LUNAR-COV19 have shown very promising findings, including the possibility that a single dose of this vaccine may be sufficient to trigger robust and durable immune responses against SARS-CoV-2. We are very eager to start the first-in-human clinical trial here in Singapore and advance LUNAR-COV19 on its journey to becoming a potential commercial vaccine.”